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Renting Valuable Assets: Knowledge and Value Production in Academic Science 
 
Clémence Pinel, PhD 
Centre for Medical Science and Technology Studies, University of Copenhagen, Denmark   
 
Abstract 
This paper explores what it takes for research laboratories to produce valuable knowledge in academic 
institutions marked by the coexistence of multiple evaluative frameworks. Drawing upon ethnographic 
fieldwork carried out in two UK-based epigenetics research laboratories, I examine the set of practices 
through which research groups intertwine knowledge production with the making of scientific, health 
and wealth value. This includes building and maintaining a portfolio of valuable resources, such as 
expertise, scientific credibility or data and turning these resources into assets by carefully organising 
and managing their value. Laboratories then put these assets to productive use within and outside their 
labs towards the creation or extraction of value. I identify two models for producing value within 
academic science: a commodity-based model whereby laboratories mobilise their assets to produce 
results, which can be converted into publications for the accumulation of credibility capital; and a rentier 
model of accumulation, whereby laboratories own valuable assets, which they rent out to others outside 
their lab against a revenue. Following recent developments in STS on value production in the 
bioeconomy, I argue that the concepts of asset and rent are essential analytical tools to get to grips with 
the origins of value within academic science. 
 
Introduction 
I think it's very difficult to define the environment. And in order to get something that is 
publishable, or worthy of funding, we just stick to very clearly defined factors, environmental 
factors that have been previously studied. (Mark, Twinomics) 
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Mark is the Principal Investigator (PI) of the epigenetics team at Twinomics, a research laboratory based 
in the UK carrying out genetics research on twins. I sit with him in his office as we discuss the work of 
his team. Epigenetics research refers to the study of the processes that control gene expression but do 
not entail a change in DNA sequence (Armstrong 2014). More specifically, research in epigenetics 
investigates the ways the ‘environment’ impacts gene regulation by leaving marks on the epigenome. 
Researchers at Twinomics explore associations between epigenetics markers and environmental factors. 
For Mark, this represents an exciting research area where discoveries could be made that could further 
“our understanding” of the interplay between environment and genes, thus contributing to the 
knowledge base in genetics and molecular biology. While there are a myriad of ways of defining the 
environment in epigenetics (Pinel, Prainsack, and McKevitt 2018), at Twinomics, they focus on specific 
environmental factors that can be “defined and measured well”, such as smoking or diet. They do so to 
ensure their research will lead to the production of results, which could be converted into publications 
in high impact-factor journals. Such publications are essential for research teams to accumulate 
credibility capital, which can help them demonstrate their “productivity” in university research audits 
(Müller 2014). They also do so because it could help them gain financial resources from funding bodies. 
As Mark later explained, the focus on specific environmental factors is also driven by the hope that 
their research will lead to therapeutic applications, with for example “a capsule that you could give to 
patients” in order to change their diet, and thus modify their epigenome. This point resonates with the 
translational research agenda, which is central to health policy, research and funding initiatives in the 
UK (Fudge et al. 2016, and in other contexts too, see for example Dam and Svendsen 2018). Under the 
translational research agenda, basic research discoveries are fostered to develop new diagnostic tests, 
drugs, devices and treatment options, which could make a difference for patients (i.e. lead to the 
production of health value1), while it could also be commercialised and rendered economically 
profitable (i.e. economic value). 
 
1 Rose and Novas (2004) identified three forms of biovalue: economic value, which entails the production of 
wealth; health value through the enhancement of health; and ethical value. 
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I begin with this scene from Twinomics because it points out that there are multiple evaluative 
frameworks folded into epigenetics research, while it shows how scientists construct their research to 
make it fit within these simultaneous evaluative frameworks. By evaluative framework I mean a set of 
evaluative principles, which are operationalised by a series of metrics, and within which “worth can 
legitimately be claimed.” (Fochler, Felt, and Müller 2016: 179). This observation from the field of 
epigenetics echoes a line of literature within STS and valuation studies that discusses the numerous 
standards through which academic performance is evaluated (Helgesson and Muniesa 2013, Rushforth, 
Franssen, and de Rijcke 2019). For example, many discuss the increasing reliance on audits within 
Higher Education and research institutions, shedding light on the effects of practices for evaluating 
performance over the type of knowledge produced, disciplines or academic selves (Hammarfelt, de 
Rijcke, and Rushforth 2016, Rijcke et al. 2015, Sigl 2016, Felt 2009). Coining terms such as ‘academic 
capitalism’ (Slaughter and Leslie 1997) or ‘entrepreneurial universities’ (Etzkowitz 2011), authors have 
also analysed the growing involvement of higher education and research institutions in the market 
economy, exploring how the evaluative framework that treats research as a business that ought to be 
profitable is embedded with academic practices (D’Este and Perkmann 2011, Hackett 2014). To discuss 
organisational settings in which multiple, and sometimes conflicting, evaluative frameworks are 
maintained and analyse how these are drawn upon by actors to inform their actions, Stark (2009) coined 
the term heterarchy2. He argued that such organisations are entrepreneurial in the ways they exploit this 
multiplicity and generate new ways of thinking by “fostering productive frictions” (ibid.: 14) between 
different modes of valuation. 
 
Building upon this body of literature, in this paper, I attend to knowledge production and value making 
practices within academic institutions marked by the coexistence of multiple evaluative frameworks. I 
 
2 Stark draws on Boltanski and Thévenot’s (2006 [1991]) sociological theory of value, in which they point to six 
“orders of worth” actors refer to when justifying their actions. 
4 
 
draw upon 12 months of ethnographic fieldwork carried out in two UK-based research groups 
conducting epigenetics research to explore how researchers in this field integrate these multiple 
evaluative frameworks to produce knowledge that can be valuable in different respects. Using the 
concept of asset, I suggest that this involves a social process that takes different forms of labour and 
knowledge, and is aimed at organising and managing value. It first entails constructing a diverse 
portfolio of resources and turning these resources into assets. It then involves mobilising these assets as 
part of the productive system that is the laboratory. I identify two main ways in which assets are used 
to produce value: either through a commodity-based model of accumulation whereby assets are used 
by members of the laboratory to create value, or through a rentier model of accumulation whereby assets 
are rented out to others outside of the lab in exchange of a fee.  
 
In this article, epigenetics research is a case study to explore valuation and knowledge production 
practices in 21st century universities. It represents an interesting case because it is a thriving field in the 
world of bioscience, with high levels of public and private funding. Its translational potential also makes 
epigenetics a good case study: it is seen as having a revolutionary potential for healthcare (Carey 2012), 
with the hope that it will provide more precise diagnostic tools and more effective therapies for many 
chronic and age-associated diseases. While this case study is concerned with epigenetics, the 
observations I make in this field, however, are relevant to other research contexts. 
 
Knowledge production, value and assets 
Within STS, a number of scholars have drawn upon the concept of capitalism as an analytical frame to 
explore how knowledge and value production are intertwined within academic science (Bourdieu 1975, 
Hackett 1990, Latour and Woolgar 1979). Fochler (2016: 924), in this journal, unpacked strategies of 
accumulation within academic research using the concept of ‘epistemic capitalism’ as denoting “the 
accumulation of capital, as worth made durable, through the act of doing research, both in and beyond 
academia.” Pointing out that academic researchers strive to accumulate different forms of capital (i.e. 
academic credibility or economic), he described a capitalist cycle whereby group leaders are concerned 
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with converting research results into publications, which can serve as assets in the competition for grant 
funding, a form of economic capital, which could then be reinvested in the laboratory. Analytically, this 
cycle of accumulation represents a useful framework to understand how different forms of value are 
fostered through academic work, at the same time that it restricts our view of value production to one 
main model, that of capital accumulation and commodification. This is because Fochler takes 
capitalisation as the starting point of his analysis of knowledge making practices and then applies it to 
the laboratory. Instead, in this paper, my analysis is first and foremost empirically grounded, and seeks 
to understand the ways value is produced within the laboratory by examining in detail the productive 
activities of the system, that is, paying attention to the different forms of labour, resources and assets 
that are mobilised to produce value (Marx 1983 [1872]). For example, what tools do researchers use 
and how? What data do they mobilise and who produces it? In other words, my analysis starts at the 
bench, exploring the resources mobilised to produce knowledge, unpacking what these resources are, 
how these are used, by whom, and how they come together in the productive system that is the 
laboratory towards the production of value.  
 
To help me unpack the productive system that constitutes the laboratory, I borrow analytical tools from 
STS scholarship on value production and assetization in the bioeconomy3 (Birch 2017, Birch and 
Tyfield 2013, Martin 2015, Geiger and Gross 2019). Authors observe that most life sciences firms fail 
to deliver on the promises of new marketed products or services, but are still highly valued. Birch (2017) 
argues that to get to grips with the origins of value in the bioeconomy, one should take into consideration 
assets and their valuation. An asset is a tradable resource that an actor owns or controls with the 
expectation that it will provide a future benefit. There are two main ways in which assets can be 
mobilised to produce value. Let’s take the example of a biotechnology firm whose main assets are a 
sequencing technology and expertise in bioinformatics. First, these assets can be used by the firm to 
 
3 The term bioeconomy is used here to refer to the set of economic activities derived from biotechnology and 
biosciences (see Pavone and Goven 2017 for the different understandings of the term bioeconomy). 
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produce commodities, such as a software to analyse sequencing data, which can be sold on the market 
to create value. Second, these assets have value as properties and can be rented out to others in exchange 
of a fee, by for example the firm turning its bioinformatics knowledge into Intellectual Property Rights 
(IPRs) from which it can earn royalties. For Birch, value in the bioeconomy results to a large extent 
from processes of assetization by which knowledge is reified and turned into a property that yields an 
income stream (for a theory of rentiership in technoscience, see Birch 2020b). Authors thus note that 
the production of value in the bioeconomy is asset-based, rather than commodity-based: value is 
constituted predominantly by ownership and control of valuable assets, rather than by the production of 
new commodities that are sold on the market. These observations lead Birch and Tyfield (2013) to argue 
that the bioeconomy is based on a “rentier regime of accumulation” whereby knowledge is made into 
valuable assets from which actors extract rents to produce value. 
 
The distinction between value creation and value extraction is relevant to this discussion. Mazzucato 
(2018: 6) defines value creation as “the ways in which different types of resources (human, physical 
and intangible) are established and interact to produce new goods and services”, which is different from 
value extraction, understood as “activities focused on moving around existing resources and outputs, 
and gaining disproportionately from the ensuing trade.” In the value creation case, assets are used as 
resources to produce commodities, while in the value extraction case, actors have control of assets, 
which can grant them a rent. This distinction between value creation and value extraction will prove 
useful to unpack the ways laboratories mobilise their assets to produce value: as I will show, the two 
laboratories studied mobilise some of their assets to extract value from rent, while in other instances 
they use their assets to create value.  
 
In short, to explore how academic research teams produce valuable knowledge, I first look into the 
resources they mobilise at the bench. I examine in detail how they construct their resources and make 
them valuable, paying attention to the set of practices they enact to turn these resources into assets, 
while I study the different ways in which they mobilise their assets to produce value. 
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Methods and the laboratories 
Ethnographic fieldwork was carried out between January 2016 and May 2017 in two research groups 
conducting epigenetics research. The first laboratory, which I term the ‘Cancer Lab’, conducts research 
into the biology of breast cancer. During the time of fieldwork, the work of the group was organised in 
two main research areas: glycobiology4 and epigenetics. Work at the Cancer Lab revolved around the 
study of two genes, which I term Gene 1 and Gene 2. Discovered and cloned by researchers in the group 
in the 1980s and 1990s, the two genes represented the common thread between the different areas of 
research the lab was involved in: while work on glycobiology focused on understanding the mechanisms 
of Gene 1, epigenetics research focused on the study of Gene 2. The lab carried out its research in a so-
called ‘wet lab’, that is, work was based on the conduct of experiments at the bench. Benchwork was a 
skilled craft that entailed a multitude of small tools, fragile materials, samples and machines. 
Researchers relied on these objects to produce data and construct a series of signs to represent the 
biological phenomenon investigated and stand for the invisible of molecular biology.  
 
The second laboratory studied, which I call ‘Twinomics’, carries out genetics research on twins based 
on a large database of clinical and research data. During fieldwork, research at Twinomics was primarily 
focused on the study of epigenetics, microbiome and transcriptomics, and explored complex diseases 
with a particular interest in age-related diseases. Work at Twinomics was centred around a twin data 
registry gathered over several decades, with clinical, physiological and lifestyle data, as well as 
hundreds of phenotypes related to common diseases. Scientists outside the lab could access and use the 
data for their own (academic or commercial) research. As a ‘dry-lab’, scientists within Twinomics 
conducted computational or applied mathematical analyses of their data. This means that researchers’ 
work did not involve standing at the bench and dealing with biological materials, but instead they 
 
4 Research in glycobiology is concerned with the study of the structure, biology and evolution of saccharides, 
sometimes also termed carbohydrates, sugar chains or glycans (Dwek 1996). 
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worked on their computers to perform experiments on datasets using statistical analysis and computer-
generated models. 
 
I spent time with researchers at the bench as they prepared and conducted experimental work, sat with 
them at their desks as they ‘ran’ computational simulations, or shared lunch and coffee breaks with 
members of the teams. Ethnographic fieldwork also involved attending the weekly team meetings 
during which researchers discussed their ‘progress’ over the past week with their PI and colleagues. I 
also accompanied the teams to conferences and seminars, observing who was present and what was 
being talked about. In addition, I conducted semi-structured interviews across the two research groups 
with laboratory leads through to junior researchers (25 in total). 
 
Making valuable assets 
In the two laboratories studied, a set of resources are drawn upon for the production of knowledge. 
Resources are sources of supply or support that can readily be mobilised for production. These include 
the laboratories’ facilities and machineries, with for example lab space and benches at the Cancer Lab. 
It also involves human resources, with Twinomics staff collecting samples from twins and producing 
datasets, or researchers conducting experiments, analysing and writing up results for publications. 
 
Some of these resources are also turned into assets. While resources can be ‘raw’ such as electricity or 
personnel, assets require labour and imply a social process: they are cultivated, rendered valuable, 
organised and managed by those who own or control them. It is also as part of this assetization process 
that resources are turned into identifiable and alienable properties ready to be mobilised as part of 
productive systems (Birch 2020b). Expertise and credibility are some of these resources turned into 
assets: the two laboratories have expertise in cancer biology and bioinformatics respectively, and 
through collaborations, conferences or publications, they continually look to enhance their reputation 
in their respective fields. For example, the Cancer Lab benefits from high credibility and expertise in 
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glycobiology. This is linked to the lab’s involvement in the discovery of Gene 1 and its role as a mucin5. 
Diana and Susan, the two senior members of the lab, who were involved in the discovery, are recognised 
as founding members of this research area. Their extensive expertise in the biology of Gene 1 and high 
scientific credibility in this field constitutes one of the Cancer Lab’s key assets. Members of the 
laboratory work towards constituting the value of this intangible asset, and in particular, this is achieved 
through relational labour, with, for instance, the organisation of a biennial conference on mucins. As 
part of fieldwork, I travelled with the group to the conference. It brought together long-term 
collaborators and new starters in glycobiology to network, discuss developments in the field, and foster 
new ideas. Throughout the three days of the conference, I observed dozens of presentations and noticed 
that most speakers referred to Gene 1 in their talk. Diana chaired two sessions during the conference, 
and speakers respectfully acknowledged her contributions by mentioning papers she published on the 
topic. Conferences like these were opportunities for the Cancer Lab to reaffirm its status as leading 
expert and assert its scientific expertise, credibility and reputation in the field of glycobiology. By 
organising such a conference, deciding on speakers, organising discussion panels, identifying the 
posters to be presented, the Cancer Lab makes and maintains the glycobiology community and places 
itself at its centre. It is through this relational labour that the laboratory converts its expertise and 
credibility into a valuable asset. 
 
The Cancer Lab also discovered Gene 2, a histone demethylase involved in epigenetics. However, work 
around Gene 2, and in epigenetics more generally, does not confer the lab as much credibility and 
reputation than research on Gene 1. They are relatively unknown in epigenetics, or as Susan put it in an 
interview, “we're known as glycobiologists, we're not known as epigeneticists.” One of the challenges 
for the Cancer Lab is to rebrand themselves as epigeneticists and show the importance of Gene 2 in this 
research field. One way in which they do so is by turning their Gene 2 expertise into a number of Gene 
2-based technologies, which can be used by researchers in and out of the laboratory. These include a 
 
5 Mucins are the main constituents of mucus. They are understood to be involved in inflammation and cancer 
(Kufe 2009). 
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Gene 2 knock-out mice strand and a Gene 2 knock-out cell line. For example, Melissa, a PhD student 
in the lab, mobilised her skills and know-how at the bench, as well as her expertise in Gene 2 and 
CRISPR-Cas9 – the latest genome editing technique – to produce the Gene 2 knock-out cell line. The 
production of this asset also required continued ‘care’ (Friese 2013) to ensure the cell line was 
functional when needed for the conduct of experiments. In the cell-culture room in the laboratory, cells 
were nursed along in flasks and plated under special environmental conditions. On a daily basis, Melissa 
came to check on her cells, watching them develop, to then periodically dividing and propagating them 
into new flasks for them to grow. With this set of practices, the Cancer Lab turns its expertise of Gene 
2 into tangible and unique assets, which can be used in and out of the laboratory for a variety of projects 
in order to explore the role of Gene 2 in cancer biology and epigenetics. 
 
Data represents another type of asset. Members of the labs enact a series of practices to make their data 
into valuable assets for the production of value within and outside the lab. This is particularly salient at 
Twinomics. The lab is well-known across the research community for its database of twins. It is 
continually being worked on, improved or added to, or as I argued elsewhere (Pinel, Prainsack, and 
McKevitt In Press), data is ‘cared for’ in a myriad of ways. This work is essential for Twinomics to 
keep the database unique and interesting for others to use. One way in which the laboratory cares for 
its data is by making the database grow through the addition of new data. This entails forging 
relationships with actors who can provide funds towards the building up of the database, including 
traditional funding bodies, pharmaceutical or biotechnology companies. In the quote below, Thor, the 
head of Twinomics, describes how he approached commercial companies to fund some of the datasets: 
 
Companies will give you money to [fund a new dataset]. It's the way I funded a lot of the 
'omics'. It's getting a company and say: "there's great technology, we combine that with great 
clinical data, this will be a great dataset for your guys to work on and our guys to work on". 
(Thor, Twinomics) 
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Expectations about what one might do with new data are mobilised to enrol partners. More specifically, 
in talks with commercial companies, Thor rebrands the twins’ data as a clinically relevant asset that 
holds promises in terms of health and wealth benefits. As such, Thor renders the twins’ data valuable 
by capitalising on hope (Martin, Brown, and Turner 2008) and turning the data into a ‘promissory asset’ 
(Martin 2015). This is another sort of practice scientists at Twinomics enact to constitute the value of 
their key asset. Twinomics thus makes its data valuable not only within the evaluative framework that 
sees research as an intellectual endeavour in search of truth, but also within the translational research 
agenda that fosters research for health and wealth benefits. 
 
The value of the database not only increases with growing numbers, but also with quality, and the range 
of datapoints included. This entails a set of practices, with, for example, staff turning the “raw” data 
produced by sequencing arrays into numbers that can be analysed computationally. Researchers 
mobilise their bioinformatics expertise and experience with large-scale datasets to format and ‘clean’ 
the laboratory’s data (Pinel 2020). Staff also make sure that every set of data is accompanied by detailed 
metadata to enable later data users to understand the context in which the data was produced. These 
data practices are enacted to turn the twins’ data into a versatile asset that can travel to other research 
teams and be used in different research projects, thus echoing Leonelli (2016) and her concept of ‘data 
curation’. But more importantly, I suggest analysing these curating practices, together with the whole 
set of data practices at Twinomics, as forming part of a process of assetization, through which the value 
of the database is made and organised. 
 
Twinomics also looks to manage the value of its database by regulating how and by whom it can be 
used. Specifically, the lab enacts limits and exclusions over the use of the data. The PIs who bring in 
new data to the lab (for example, thanks to a successful funding application) are in charge of overseeing 
its use. For example, Mark, the PI of the epigenetics team, oversees the use of the DNA methylation 
data at Twinomics. He grants access to researchers in and out of the lab who wish to use the data. When 
considering ‘data access requests’ from collaborators, he evaluates whether the proposed projects 
“clash” with any of his existing research: “If it clashes, then we ask them to alter it [the proposed project] 
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and tell them that this clashes, so we can approve this and not that.” Access to the data therefore also 
comes with forms of exclusion, as the lab encloses its data within its walls to then distribute access 
rights under specific conditions. As part of the assetization process at Twinomics, the lab therefore 
constructs its data as an alienable, yet exclusive, asset.  
 
For the two laboratories studied, the production of value starts by turning some their resources into 
assets that can be used within and outside their laboratories as part of productive systems. Members of 
the labs mobilise their skills, expertise and networks to make these assets valuable, while they 
implement a set of practices to manage them as unique and exclusive assets. Next, I unpack the different 
ways in which these assets are mobilised to produce value.  
 
In-house value production 
In the two laboratories studied, there are two main ways in which assets are mobilised towards the 
production of value. In the first model, a number of assets are used and combined to produce 
commodities, which are then sold on a market to create value. At Twinomics, this model entails 
researchers using the twins’ data together with their expertise and computational tools to produce 
research results that can be written up for publication towards the production of epistemic value, which 
can then be mobilised as tokens of credibility in the competition for grant funding (economic value). 
Specifically, epigenetics research projects are based on the use of DNA methylation data. While these 
projects differ in their aims, they have two things in common: every project is overseen by Mark, the 
PI of the epigenetics team, and they all borrow the “epigenetics pipeline” to conduct the analysis. 
 
This model of knowledge and value production was particularly apparent in a project undertaken by 
Olivia and Maria, two post-docs at Twinomics. During fieldwork, they were starting a research project 
together exploring environmental influences over DNA methylation. I followed their progress, joining 
them in meetings, observing them at their desks, or being copied in email conversations. One afternoon, 
I joined Olivia and Maria as they met to discuss the project. They were considering what environmental 
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factor to study in association with DNA methylation. Smoking is the first one they considered and 
agreed on. Olivia argued that smoking is “a very strong environmental factor”, meaning that it could 
lead to the production of results that could easily be interpreted and converted into publications. She 
added that it made sense to choose this environmental factor because the data was “clean” and 
discordant analysis was possible. Put differently, the availability of data and the likelihood of producing 
epistemic value drove the choice of research question. Then Olivia said, “we should talk to Mark about 
our plans.” At Twinomics, Mark acts as the ‘guardian’ to the DNA methylation datasets. This means 
deciding on the projects that can use the datasets, as well as overseeing the way they are used by 
providing feedback on the analysis and the writing up of results. By helping develop the twins’ data 
over the years, Mark ‘knows’ his data, that is, he has contextual and practical knowledge about what a 
dataset seeks to represent, its strengths and limitations. When Olivia and Maria discuss their project 
with Mark, they are not only granted access to the DNA methylation data, but they also receive input 
about how to ‘deal’ with the data in their work so as to make the most of it towards the production of 
valuable research. In particular, they are reminded by Mark that to conduct the analysis on the DNA 
methylation data, they should apply “the analysis pipeline”, which was developed by Katherine, another 
post-doc on the epigenetics team, together with Mark. It consists of a detailed plan indicating how to 
go about analysing the DNA methylation data computationally using a ‘twin model’, with steps and 
sub-steps and the necessary “scripts” to use in each step. This pipeline functions like a ‘standardised 
package’ (Fujimura 1996) providing researchers on the epigenetics team with an established route to 
produce results based on the twins’ data. This is what Maria suggests in the quote below:  
 
Now we are starting something completely new, but every time that we are doing an 
association study, you take the “Katherine data”, the “Katherine covariate”, the “Katherine 
formula” and you run. (Maria, Twinomics) 
 
Through this analysis pipeline, Mark imposes limits on how the twins’ data can be used. In addition, as 
Mark selectively grants access to ‘his’ datasets, he gains authorship on future publications, therefore 
extracting epistemic value from the productive endeavour. Mark’s authorship thus constitutes value that 
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is derived from the ownership of exclusive assets (see next section for more detail about the process of 
value extraction).  
 
In this project, value is produced using only the laboratory’s resources and assets – i.e. the lab’s facilities 
and machines, the twins’ data, the analysis pipeline, the laboratory’s staff. These assets are mobilised 
within the lab to create something valuable, that is, research results, which are written up for publication 
for academic peer-reviewed journals. In other words, research results function like commodities, which 
are mobilised and sold on a market – academic peer reviewed journals – against epistemic value. The 
epistemic value accumulated can then serve as tokens of credibility for members of the lab, which they 
can mobilise in competition for grant funding, another market, to accumulate economic value, which in 
turn can be reinvested in the laboratory. This represents an ‘in-house’ model of value production, 
whereby something of value is created within the walls of Twinomics, by members of the lab and using 
only the laboratory’s resources and assets. The value of the commodity produced ‘in house’ is then 
negotiated and ascribed in interaction with actors outside the lab, such as academic peer-reviewed 
journals. However, as the granting of authorship to PIs like Mark suggests, ‘in-house’ value creation at 
Twinomics also comes with forms of value extraction, whereby value is also produced from the 
ownership and control of exclusive assets. 
 
The dissemination of results produced at Twinomics through publications or conferences, apart from 
fostering epistemic value for members of the lab, is also aimed at enhancing the value of the twins’ 
database. During fieldwork, I was invited to observe a post-doc rehearsing a conference presentation. 
After introducing the project’s aims in the first slide, he spent the next two slides discussing the data 
used: the first slide showed the database’s logo with a broad description of the twins’ database, while 
also discussing the dataset used in this project; the second slide contained a detailed table showing the 
different phenotypes and variables used. He then spent the next five slides discussing the results of the 
study, and concluded by giving a brief summary of what the project achieved and linked this to the data 
used, its strengths and limitations. Such dissemination exercise enables Twinomics to do two things: 
foster its credibility within the research community on the one hand, and build the name of its database 
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on the other. Describing research results in close relation to the data used helps Twinomics show others 
what the twins’ data can achieve. This may lead to collaborations with teams outside the lab interested 
in accessing portions of datasets for their own projects (see next section).  
 
In sum, the production of valuable research in the epigenetics team at Twinomics first and foremost 
entails paying attention to their core asset, the DNA methylation data: the questions researched are 
driven by what the data enables them to do, how they study the research problem is standardised around 
an analysis pipeline developed to fit the data, they disseminate results by heavily acknowledging the 
twins’ database, while the overall process is overseen by the PI of the epigenetics team, who ‘guards’ 
the data. In conducting research on the DNA methylation data, researchers create value fostering their 
scientific credibility, while enhancing and managing the value of their database.  
 
Renting out valuable assets  
In the concurrent model of value production, actors own valuable assets, which they rent out to others 
in exchange of a revenue. Across the two laboratories studied, this model entails different sorts of assets, 
practices and relationships between actors. For the Cancer Lab, growth is about maintaining or 
enhancing their credibility and expertise around their two genes. While the Cancer Lab is widely known 
in glycobiology, this is not the case in epigenetics. As Susan explained to me in an interview, “being 
relatively unknown in epigenetics”, they have been struggling to secure funding for their epigenetics 
research. To tackle this challenge, the Cancer Lab connects with other laboratories conducting 
epigenetics research and trades some of its assets, namely their Gene 1 credibility and Gene 2 knock-
out mice strand. The vignette below illustrates well the trading of assets. 
 
“Come in” says Diana as I knock on her door. We have scheduled to meet for an interview. I sit down 
on the chair across her desk, while she types on her computer. After a minute, Diana looks up and 
apologies for keeping me waiting. She explains that the lab is applying for funding with another research 
team with expertise and credibility in epigenetics to conduct a study of the role of Gene 2 in intellectual 
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disability. Diana is a co-applicant on the grant and she is completing a section in the application about 
herself. She was specifically asked by the lead applicant, a more junior scientist, to write in her H index. 
It is a common indicator of research impact, which is calculated based on a scientist’s most cited papers 
and the number of citations these papers have received. She says, “the Gene 1, it’s right up there”, 
meaning that papers discussing the Gene 1 discovery are on the top of her H index. The Cancer Lab 
provides its credibility and reputation from Gene 1 research to add strength to the grant application and 
enhance their chances of securing financial capital. The Cancer Lab also provides its Gene 2 knock-out 
mice strand for the conduct of experiments. This gives rise to a specific trade deal, as Diana suggests, 
“[our co-applicant] wants to use our mice. … We offer him the mice and he will do the experiments.” 
While the Cancer Lab makes these two assets available, it is their partner who is involved in the actual 
doing of research and the production of results. That is, it is their collaborator who creates value from 
the available assets. However, by providing its assets for the conduct of the project, the Cancer Lab 
gains a revenue, in terms of grant money and authorship on publications. Put differently, in this scenario, 
the Cancer Lab extracts value from its assets.  
 
At Twinomics, a similar model of value production exists, but it is primarily based on a different sort 
of asset, namely the laboratory’s data. With its unique database, a series of actors, including academic 
research groups, biotechnology and pharmaceutical companies reach out to Twinomics to gain access 
to portions of datasets. The laboratory turns data into a tradable and mobile asset, at the same time that 
it imposes limits and conditions around its use. As I pointed out earlier, not every ‘data access request’ 
is granted, with some portions of the database remaining inaccessible to outsiders. Twinomics may 
demand that changes be made to project proposals, while they also request that new variables derived 
from the data be returned to the lab. Once access is granted, collaborators use Twinomics’ data together 
with other assets to produce results for the creation of value. In this configuration, Twinomics receives 
a revenue from the trade: in exchange for using Twinomics’ data, collaborators pay a financial 
contribution and grant authorship or acknowledgements to the lab on publications. Twinomics uses this 
financial capital to ‘buy’ human and material resources towards the maintenance of its database. The 
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publications earned from the trade are tokens of credibility, which Twinomics mobilises in the 
competition for grant funding. 
 
This constitutes a rentier model of value production and accumulation, whereby the two laboratories 
own a number of valuable assets, from which it yields rents to produce value. This model first entails 
laboratories turning their assets into tradable assets that can be rented out to others against a revenue. 
They make their assets available to collaborators, who use them to produce results and create value. 
The laboratories then receive a revenue from the trade, as financial capital, credibility and authorship 
on publications: it is a form of rent, in that it is an income derived from the ownership of valuable assets. 
As such, in these collaborations, the laboratories mobilise its assets to extract value, rather than create 
it itself.  
 
Discussion 
Across the two laboratories studied, the production of value first starts by building and maintaining a 
portfolio of valuable resources, and turning these resources into assets. The laboratories mobilise these 
assets to produce knowledge and value. I identified two main ways in which they do so. First, the 
laboratories create value by mobilising their assets and producing results, which they convert into 
epistemic credit that can be mobilised in the competition for grant funding towards the accumulation of 
economic capital. Second, the laboratories trade with other research teams some of their assets against 
a revenue, in the form of authorship or acknowledgements on publications, or financial capital – as 
such, they extract value from their assets.  
 
The two models of value creation and value extraction, while functioning on different bases, share some 
common grounds, and in particular they both rest on the active and ongoing management of assets. The 
two laboratories carefully construct, organise and manage a number of assets in order to derive value 
from productive endeavours. Laboratories are particularly concerned with asserting ownership and 
control over its assets, as they impose limits over the use of their assets. They do so in order to render 
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their assets exclusive, which enables them to selectively distribute access rights to others, to then yield 
a revenue. As such, the creation and extraction of value are deeply intertwined with assetization 
processes. In addition, such assetization and value making practices are linked to specific labour 
relations within the two laboratories: while PIs are usually involved in making decisions about which 
assets to invest in, while they also negotiate and control how value is extracted from the assets, it is 
junior staff who makes and maintains such assets. At the Cancer Lab for example, Susan the PI decided 
to mobilise the lab’s expertise to develop the Gene 2 knock-out mice strand, while it is through her 
networks that she forged a collaboration based on the trading of this technology. However, it was post-
docs and PhD students who used their skills at the bench to produce this asset, rendering it operational 
for the production of valuable research. Once this technology was rented out to collaborators, Susan 
extracted value from the process by being granted authorship on publications. Resonating with critical 
labour studies (Gill 2014), one could argue that the production of value in such cases rests on the 
exploitation of junior staff who are alienated from their work, while senior staff extract surplus value 
that workers produce.  
 
The rentier model of value production and accumulation is essential to understanding the ways in which 
academic research laboratories integrate different evaluative frameworks into their work. Instead of 
acquiring all the necessary assets to produce knowledge that can be valuable within the different 
evaluative frameworks at play in academic institutions, research teams concentrate on building a 
number of key assets. They make their assets available for productive use within the research 
community, renting them out to their networks, while gaining a revenue from the trade. By doing so, 
the teams move in and out of projects, fields and evaluative frameworks, extracting value as they go. It 
is around their key assets – expertise and credibility in glycobiology at the Cancer Lab, and twins’ data 
at Twinomics – that the two labs can most easily relate to the different evaluative frameworks at play 
in academic science. They are well-known for having developed such assets, which means that a broad 
range of actors, from research teams to commercial firms, regularly approach them to rent these assets 
against payment.  
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The observations I make in this paper, while based on the field of epigenetics, are relevant to other 
research fields. The production of value is a social process that entails a set of actors, knowledge and 
practices. And in particular, it involves making, maintaining and mobilising assets as part of productive 
systems. One could argue, however, that what may differ across fields are the sort of assets these value 
making processes depend on. While in the two labs discussed here, value is intimately linked to model 
organisms or databases, these assets would not be as central in other academic fields such as in the 
humanities or social sciences, where credibility or expertise might have more of a dominant role. Further 
empirical work is needed to test and unpack such assetization and value making practices across fields, 
while it would also be interesting to explore how assets which differ in their materialities and qualities 
relate to particular models of value production.  
 
Conclusion 
In this conclusion, I discuss what these findings teach us about contemporary knowledge production, 
valuation and theory. I identify three main lessons. First, findings underline how knowledge production 
is intertwined with valuation processes. Research laboratories are concerned with producing knowledge 
that can be valuable in different respects. I underlined that processes of assetization, whereby value 
production rests on the ownership, maintenance and renting of assets, are central to these knowledge 
production and valuation practices. Contributing to discussions on valuation, this work provides further 
empirical and analytical grounding to the question of what gets valued and how in the knowledge 
economy (Birch 2017, Geiger and Gross 2019). This article also makes theoretical contributions to the 
body of work on (e)valuation in academic science and heterarchical organisations. Considering the 
laboratory as a productive system made of resources and assets invites us to look beyond the seeming 
conflict between evaluative frameworks, and get to grips with the origins of value. Furthermore, this 
article invites discussions on assetization and rentiership to the domain of academic science, 
demonstrating that they do not just constitute a growing phenomena in innovation strategies within high 
tech for example (Birch 2020a, Mazzucato 2018). The expansion of rentiership and assetization 
practices to academic science is grounded on a set of assets, such as model organisms or databases, as 
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well ‘traditional’ resources within science such as credibility and reputation. This observation comes in 
complement of existing work on assetization (Birch 2017, 2020b), which has mostly discussed one sort 
of asset, that is, technoscientific knowledge turned into IPRs. I thus broaden the conceptual applicability 
of the concept of rent, by pointing out that credibility and reputation in academic science also make 
intangible assets that form the basis of a rentier model of value production and accumulation.  
 
Second, the rentier model of value production and accumulation I presented here sheds new light on the 
collaborative nature of academic work. What is at stake in the research collaborations discussed is the 
trading of valuable assets. While laboratories own a few key assets, through their network of 
collaborators, they build extended portfolios of assets. Laboratories make their assets available to others 
in the scientific community, trading them against other assets or a revenue. As such, research networks 
rest on trading relationships, with valuable assets at its core. These are different trading relationships 
than the ones discussed by Collins and colleagues (Collins, Evans, and Gorman 2007: 665), which are 
based on expertise and where trading zones function “as places where cultures meet, languages are 
learned and tacit knowledge shared.” Instead here, I look at research collaborations through its material 
dimension and suggest that what brings collaborators together are assets (which can take the shape of 
expertise). Value production through research collaborations is only possible if laboratories are well 
connected and well-known for their assets. The bigger their network, the more opportunities a lab has 
to trade its assets and accumulate value. Laboratories continually look to build their networks, for 
example by regularly attending and presenting at conferences. In such instances, staff connect with 
former and new collaborators, become familiar with ongoing research based on others’ assets, while 
they also promote the value of their own assets by showing the type of results it can produce. In other 
words, in these events, laboratories scrutinise the supply and demand for assets, and position themselves 
and their assets in this market.  
 
Third, the knowledge and value making practices discussed have important implications, starting for 
the type of knowledge produced. In the two laboratories studied, new research projects were not just 
considered in terms of their potential epistemic value, but also for the ways they could help them 
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enhance the value of their assets, while the process of producing results and disseminating them was 
also deeply concerned with constituting and managing the value of their assets. In other words, what 
and how knowledge was produced was tightly linked to assetization processes. This suggests that 
entrepreneurial science, marked by the imperative to produce knowledge that can be valuable in 
different respects, not only matters for researchers and their practices at the bench, but it matters for 
patients and citizens alike in that it shapes what we know about the world and our health. Building on 
that observation, further empirical work is needed to demonstrate and unpack how such assetization 
processes influence the content of science.  
 
Acknowledgements 
My first thanks go to staff in the two laboratories studied who generously let me into their daily work, 
and enthusiastically shared their experiences and knowledge. I am indebted to Christopher McKevitt 
and Barbara Prainsack, for their continued mentorship, guidance and insightful comments on this work. 
Finally, I wish to thank members of the MeInWe team at the University of Copenhagen for their support 
and feedback on earlier versions of this article.  
 
Funding 
This work was supported by the Wellcome Trust [grant number WT108574MA], and the Carlsberg 
Foundation [grant number CF17-0016]. 
 
References 
Armstrong, Lyle. 2014. Epigenetics. London: Garland Science. 
Birch, Kean. 2017. "Rethinking Value in the Bio-economy: Finance, Assetization, and the Management 
of Value."  Science, Technology, & Human Values 42 (3):460-490. 
Birch, Kean. 2020a. On data rentiership in 'Big Tech': Why Silicon Valley might not be the innovation 
model we're looking for. Discover Society (8 January). Accessed 14 January 2020. 
Birch, Kean. 2020b. "Technoscience Rent: Toward a Theory of Rentiership for Technoscientific 
Capitalism."  Science, Technology & Human Values 45 (1):3-33. 
Birch, Kean, and David Tyfield. 2013. "Theorizing the Bioeconomy: Biovalue, Biocapital, 
Bioeconomics or . . . What?"  Science, Technology, & Human Values 38 (3):299-327. 
22 
 
Boltanski, Luc, and Laurent Thévenot. 2006 [1991]. On justification: The economies of worth. 
Cambridge: Polity. 
Bourdieu, Pierre. 1975. "The specificity of the scientific field and the social conditions of the progress 
of reason."  Information (International Social Science Council) 14 (6):19-47. 
Carey, Nessa. 2012. The Epigenetics Revolution: How Modern Biology is Rewriting Our Understanding 
of Genetics, Disease and Inheritance. New York: Columbia University Press. 
Collins, Harry, Robert Evans, and Mike Gorman. 2007. "Trading zones and interactional expertise."  
Studies in History and Philosophy of Science Part A 38 (4):657-666. 
D’Este, Pablo, and Markus Perkmann. 2011. "Why do academics engage with industry? The 
entrepreneurial university and individual motivations."  The Journal of Technology Transfer 36 
(3):316-339. 
Dam, Mie S., and Mette N. Svendsen. 2018. "Treating pigs: Balancing standardisation and individual 
treatments in translational neonatology research."  BioSocieties 13 (2):349-367. 
Dwek, Raymond. 1996. "Glycobiology:  Toward Understanding the Function of Sugars."  Chemical 
Reviews 96 (2):683-720. 
Etzkowitz, Henry. 2011. "Normative change in science and the birth of the Triple Helix."  Social Science 
Information 50 (3-4):549-568. 
Felt, Ulrike. 2009. Knowing and Living in Academic Research: Convergence and Heterogeneity in 
Research Cultures in the European Context. Prague, Czech Republic: Institute of Sociology of 
the Academy of Sciences of the Czech Republic. 
Fochler, Maximilian. 2016. "Variants of Epistemic Capitalism: Knowledge Production and the 
Accumulation of Worth in Commercial Biotechnology and the Academic Life Sciences."  
Science, Technology, & Human Values 41 (5):922-948. 
Fochler, Maximilian, Ulrike Felt, and Ruth Müller. 2016. "Unsustainable Growth, Hyper-Competition, 
and Worth in Life Science Research: Narrowing Evaluative Repertoires in Doctoral and 
Postdoctoral Scientists’ Work and Lives."  Minerva 54 (2):175-200. 
Friese, Carrie. 2013. "Realizing Potential in Translational Medicine. The Uncanny Emergence of Care 
as Science."  Current Anthropology 54 (S7):S129-S138. 
Fudge, Nina, Euan Sadler, Helen R. Fisher, John Maher, Charles D. Wolfe, and Christopher McKevitt. 
2016. "Optimising Translational Research Opportunities: A Systematic Review and Narrative 
Synthesis of Basic and Clinician Scientists' Perspectives of Factors Which Enable or Hinder 
Translational Research."  PLOS ONE 11 (8):e0160475. 
Fujimura, Joan H. 1996. Crafting Science: A Sociohistory of the Quest for the Genetics of Cancer. 
Cambridge, MA: Harvard University Press. 
Geiger, Susi, and Nicole Gross. 2019. "A Tidal Wave of Inevitable Data? Assetization in the Consumer 
Genomics Testing Industry."  Business & Society Advance online publication. 
Gill, Rosalind. 2014. "Academics, Cultural Workers and Critical Labour Studies."  Journal of Cultural 
Economy 7 (1):12-30. 
Hackett, Edward J. 1990. "Science as a Vocation in the 1990s."  The Journal of Higher Education 61 
(3):241-279. 
Hackett, Edward J. 2014. "Academic Capitalism."  Science, Technology, & Human Values 39 (5):635-
638. 
Hammarfelt, Björn, Sarah de Rijcke, and Alexander Rushforth. 2016. "Quantified academic selves: the 
gamification of research through social networking services."  Information Research 21 (2). 
Helgesson, Claes-Fredrik, and Fabian Muniesa. 2013. "For What It’s Worth: An Introduction to 
Valuation Studies."  Valuation Studies 1 (1):1-10. 
Kufe, Donald W. 2009. "Mucins in cancer: function, prognosis and therapy."  Nature Reviews Cancer 
9 (12):874-885. 
Latour, Bruno, and Steve Woolgar. 1979. Laboratory Life. The Construction of Scientific Facts. 
Princeton: Princeton University Press. 
Leonelli, Sabina. 2016. Data-Centric Biology: A Philosophical Study. Chicago: University of Chicago 
Press. 
Martin, Paul. 2015. "Commercialising neurofutures: Promissory economies, value creation and the 
making of a new industry."  BioSocieties 10 (4):422-443. 
23 
 
Martin, Paul, Nik Brown, and Andrew Turner. 2008. "Capitalizing hope: the commercial development 
of umbilical cord blood stem cell banking."  New Genetics and Society 27 (2):127-143. 
Marx, Karl. 1983 [1872]. Capital: A Critique of Poilitcal Economy. Volume I. London: Lawrence & 
Wishart. 
Mazzucato, Mariana. 2018. The Value of Everything. Making and Taking in the Global Economy. UK: 
Allen Lane. 
Müller, Ruth. 2014. "Racing for What? Anticipation and Acceleration in the Work and Career Practices 
of Academic Life Science Postdocs."  Forum: Qualitative Social Research 15 (3). 
Pavone, Vincenzo, and Joanna Goven. 2017. "Introduction." In Bioeconomies. Life, Technologies, and 
Capital in the 21st Century, edited by V. Pavone and J. Goven, 1-22. Cham, Switzerland: 
Palgrave Macmillan. 
Pinel, Clémence. 2020. "When more data means better results: Abundance and scarcity in research 
collaborations in epigenetics."  Social Science Information Advance online publication. 
Pinel, Clémence, Barbara Prainsack, and Christopher McKevitt. 2018. "Markers as mediators: A review 
and synthesis of epigenetics literature."  BioSocieties 13 (1):276-303. 
Pinel, Clémence, Barbara Prainsack, and Christopher McKevitt. In Press. "Caring for data: Value 
creation in a data-intensive research laboratory."  Social Studies of Science. 
Rijcke, Sarah de, Paul F. Wouters, Alex D. Rushforth, Thomas P. Franssen, and Björn Hammarfelt. 
2015. "Evaluation practices and effects of indicator use—a literature review."  Research 
Evaluation 25 (2):161-169. 
Rose, Nikolas, and Carlos Novas. 2004. "Biological citizenship." In Global assemblages: technology, 
politics, and ethics as anthropological problems, edited by A. Ong and S. Collier, 439–463. 
Oxford: Blackwell. 
Rushforth, Alexander, Thomas Franssen, and Sarah de Rijcke. 2019. "Portfolios of Worth: Capitalizing 
on Basic and Clinical Problems in Biomedical Research Groups."  Science, Technology, & 
Human Values 44 (2):209-236. 
Sigl, Lisa. 2016. "On the Tacit Governance of Research by Uncertainty: How Early Stage Researchers 
Contribute to the Governance of Life Science Research."  Science, Technology, & Human 
Values 41 (3):347-374. 
Slaughter, Sheila, and Larry Leslie. 1997. Academic Capitalism. Baltimore/London: The John Hopkins 
University Press. 
Stark, David. 2009. The sense of dissonance. Accounts of worth in economic life. Princeton/Oxford: 
Princeton University Press. 
 
Author biography 
Clémence Pinel is a postdoc in the MeInWe team (https://meinwe.ku.dk/) within the Centre for Medical 
Science and Technology Studies, University of Copenhagen. In 2018, she completed her PhD at King’s 
College London and was awarded the Doctoral Prize from the UK Association for Studies in Innovation, 
Science and Technology (AsSIST-UK). Her work focuses on knowledge production and valuation 
practices in the life sciences, with a specific interest for data-intensive research. 
 
